SCHEMBL10154050

SCHEMBL10154050

CNCC1CCN(c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
CARM1 Q86X55 3/20 0.48
PRMT6 Q96LA8 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
MBTD1 Q05BQ5 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
CHRNA7 P36544 3/20 0.46
ACHE P22303 2/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
NPC1 O15118 1/20 0.44
CXCR4 P61073 1/20 0.44
KDM1A O60341 1/20 0.44
DRD2 P14416 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9970754 0.90 MAPT (0.49) ADRA1DADRA1AADRA1BCARM1PRMT6
SCHEMBL12916521 0.84 MEN1 (0.51) ADRA1DADRA1AADRA1BL3MBTL1HRH3
SCHEMBL785012 0.83 ROCK2 (0.54) L3MBTL1HRH3KDM1ADRD2
Hydrochloric Acid SCHEMBL786057 0.81 ROCK2 (0.53) L3MBTL1HRH3KDM1ADRD2
SCHEMBL19700585 0.81 ADRA1D (0.48) ADRA1DADRA1AADRA1BL3MBTL1MBTD1
SCHEMBL21101616 0.81 ADRA1D (0.50) ADRA1DADRA1AADRA1BL3MBTL1MBTD1
SCHEMBL424881 0.79 CHRNA7 (0.55) L3MBTL1MBTD1L3MBTL3HRH3CHRNA7
SCHEMBL946519 0.79 HRH3 (0.52) CARM1PRMT6L3MBTL1HRH3SLC6A2
SCHEMBL4071616 0.78 ADRA1D (0.51) ADRA1DADRA1AADRA1BL3MBTL1MBTD1
SCHEMBL23588495 0.78 SIGMAR1 (0.51) ADRA1DADRA1AADRA1BL3MBTL1MBTD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-05 US disclosed
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-05 US disclosed
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 ADRA1D 1933/4885ADRA1A 1810/4885ADRA1B 1607/4885
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA ADRA1D 851/4885ADRA1A 1447/4885ADRA1B 1247/4885
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF VHL, MDM2, NEDD4 ADRA1D 2759/4885ADRA1A 3026/4885ADRA1B 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.